Want to see OTLK full AI Analyst Report?
OTLK Stock Chart & Stats
$1.40
-$0.07(-5.34%)
At close: 4:00 PM EDT
$1.40
-$0.07(-5.34%)
Day’s Range― - ―
52-Week Range$0.16 - $3.39
Previous CloseN/A
Volume462.68K
Average Volume (3M)13.68M
Market Cap
$187.00M
Enterprise Value$36.28
Total Cash (Recent Filing)$7.75M
Total Debt (Recent Filing)$27.19M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 13, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding186,997,000
10 Day Avg. Volume13,491,520
30 Day Avg. Volume13,678,892
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.15
Price to Sales (P/S)26.09
P/FCF Ratio-0.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.20Price Target Upside271.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$16.14M
Bulls Say, Bears Say
Bulls Say
FDA Approval Of LYTENAVAReceiving U.S. FDA approval makes Outlook the first approved ophthalmic bevacizumab provider in the U.S., creating a structural market-entry advantage into the roughly $8.5B retina market. This approval underpins a durable commercial path and legitimizes reimbursement and specialist adoption efforts.
12-year Biologics ExclusivityA 12-year exclusivity window under the U.S. biologics framework materially lengthens the company’s protected commercial runway, limiting immediate biosimilar competition, allowing multi-year market-share buildout and amortization of commercialization investments.
Regulatory Momentum And Labeling ProgressThe FDA’s Class 1 acceptance and prior successful appeal reduce regulatory execution risk. Demonstrated ability to resolve a Complete Response Letter and work on labeling indicates durable regulatory engagement and a higher probability of sustained market access and stable product labeling.
Bears Say
Persistent Operating LossesAcross reported periods the company shows deep net losses and negative gross profit where revenue exists. Such structural unprofitability implies the business must materially improve margins and scale commercial volumes to reach sustainable earnings, a multi-quarter to multi-year challenge.
Chronic Cash BurnConsistent negative operating and free cash flow indicate the company lacks self-funding capacity. Even with product approval, commercialization will require sizable working capital and marketing investment, leaving persistent dependence on external financing and execution risk over months to years.
Reliance On Equity And Dilution RiskApproving a large increase in authorized shares alongside recent registered direct, insider-backed and ATM transactions signals continued reliance on equity financing. This structural funding approach raises long-term dilution risk and can constrain shareholder returns as commercialization scales.
Outlook Therapeutics News
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.16 and its highest was $3.39 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $187.00M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 13 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on May 15, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.121 by -$0.039.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 186,997,000 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.121. Following the earnings report the stock price went up 0.439%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outlook Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.20 (271.43% Upside)
$5.20 (271.43% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 151.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.77%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
OTLK Stock 12 Month Forecast
Average Price Target
$5.20
▲(271.43% Upside)
Technical Analysis
Ownership Overview
12.20% Insiders
1.20% Mutual Funds
0.46% Other Institutional Investors
83.83% Public Companies and
Individual Investors